{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:08:03Z","timestamp":1792681683404,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020284","name":"Shire Human Genetic Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eprac.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T10:37:39Z","timestamp":1702204659000},"page":"200-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism"],"prefix":"10.1016","volume":"30","author":[{"given":"Mishaela R.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Cusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tokareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olulade","family":"Ayodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Finkelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice. Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000486060","article-title":"Physiology of the calcium-parathyroid hormone-vitamin D axis","volume":"50","author":"Goltzman","year":"2018","journal-title":"Front Horm Res"},{"key":"10.1016\/j.eprac.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2023.12.001_bib5","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s12325-021-01649-2","article-title":"Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Ketteler","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2023.12.001_bib8","unstructured":"Natpar summary of product characteristics Takeda Pharmaceuticals International AG. Accessed 19 May 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/natpar-epar-product-information_en.pdf"},{"key":"10.1016\/j.eprac.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jbmr.4780","article-title":"The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1-84)","volume":"38","author":"Agarwal","year":"2023","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2023.12.001_bib15","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.clinthera.2017.08.011","article-title":"Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-\u03bcg or 50-\u03bcg daily doses","volume":"39","author":"Bilezikian","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.eprac.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/PROM.S179310","article-title":"Psychometric evaluation of the hypoparathyroidism symptom diary","volume":"10","author":"Coles","year":"2019","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.eprac.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.eprac.2023.12.001_bib19","first-page":"W32","article-title":"Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-Perceived Cognitive Function Instrument","volume":"7","author":"Wagner","year":"2009","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.eprac.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.eprac.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.eprac.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1258\/acb.2011.011078","article-title":"Pathology Harmony; a pragmatic and scientific approach to unfounded variation in the clinical laboratory","volume":"48","author":"Berg","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.eprac.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(82)90567-8","article-title":"Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1.25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects","volume":"72","author":"Coe","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.eprac.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/07853890109002089","article-title":"The RAND-36 measure of health-related quality of life","volume":"33","author":"Hays","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.eprac.2023.12.001_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-item health survey 1.0","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ"},{"key":"10.1016\/j.eprac.2023.12.001_bib27","first-page":"521","article-title":"Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients","volume":"18","author":"Yokum","year":"2008","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.eprac.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/cen.14813","article-title":"The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): a retrospective cohort study","volume":"98","author":"Rejnmark","year":"2023","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.eprac.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six-year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/jbmr.2812","article-title":"Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism","volume":"31","author":"Sikjaer","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1590\/S0004-27302010000200019","article-title":"Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement","volume":"54","author":"Rubin","year":"2010","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.eprac.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2002-021388","article-title":"Increased bone mineral density in patients with chronic hypoparathyroidism","volume":"88","author":"Chan","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.eprac.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:46Z","timestamp":1761516946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23007784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1530891X23007784"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.001","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Takeda Development Americas, Inc. Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinologists.","name":"copyright","label":"Copyright"}]}}